前列腺癌，細胞凋亡，抗體:藥物開發策略分析 是由出版商BioSeeker Group AB在2011年12月所出版的。
這份英文市場調查報告書包含4399 Pages 價格從美金5175起跳。
本報告以前列腺癌的藥物開發策略上細胞凋亡的機制、目標、影響領域和抗體的化合物領域為焦點，彙整各種的藥劑目標策略，化合物策略競爭基準，開發平台及最佳投資組合計劃等等資料，為您概述為以下內容。
第1章 前列腺癌
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:各開發階段的前列腺癌治療藥物目標策略
- 使用中的化合物策略:前列腺癌治療藥物各化合物策略競爭基準
- 開發平台·最佳投資組合計劃:前列腺癌治療藥物開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第2章 細胞凋亡
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:細胞凋亡治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:細胞凋亡藥物的各類型化合物的競爭基準
- 細胞凋亡的癌適應症症狀選擇
- 最佳投資組合計劃:細胞凋亡開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第3章 抗體
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:癌症的抗體治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 抗體治療藥物的癌適應症症狀的選擇
- 最佳投資組合計劃:癌症的抗體治療開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
Abstract
Description
This triple analysis focuses on cancer drug development strategies in one
specific cancer indication (Prostate Cancer), one mechanism/target/effect area
(Apoptosis) and one compound specific area (Antibodies).
Below is a short synopsis of each part included in this report:
Part I: Prostate Cancer
The prostate cancer report part comprises defined and up to date development
strategies for 346 prostate cancer drugs within the portfolio of 198
investigators, from Ceased to Marketed. This report part extensively analyses
202 identified targets of prostate cancer drugs, organized into 187 drug
target strategies, and assesses them in prostate cancer.
Part II: Apoptosis
The apoptosis report part comprises defined and up to date development
strategies for 171 apoptotic drugs in oncology (519 projects) within the
portfolio of 125 investigators, from Ceased to Pre-registration. This report
part extensively analyses 146 identified targets of apoptotic drugs, organized
into 120 drug target strategies, and assesses them in 53 different cancer
indications.
Part III: Antibodies
The cancer antibody drug report part comprises defined and up to date
development strategies for 531 antibody drugs in oncology within the portfolio
of 196 companies world-wide, from Ceased to Marketed. The report extensively
analyses their 255 identified drug targets, organized into 266 drug target
strategies, and assesses them in 75 cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Prostate Cancer
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (202 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies by
their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug
Target Strategies and 346 Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Prostate
Cancer Drugs by Compound Strategy (8 Different Compound Strategies)
- 9. Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate
Cancer Therapeutic Pipeline by Investigator (198 Investigators)
- 11. Drug Index
- 12. Company Index
- Figures: Includes 6 Figures
- Tables: Includes 257 Tables
- Total Number of Pages: 838
Part II: Apoptosis
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (146 Drug Targets)
- 7. The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic
Pipeline? (120 Drug Target Strategies and 171 Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Apoptotic
Drugs in Oncology by Compound Type (7 Different Compound Strategies)
- 9. Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer
Indications)
- 10. Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer
Therapeutic Pipeline by Investigator (125 Investigators)
- 12. Drug Index
- 13. Company Index
- Figures: Includes 6 Figures
- Tables: Includes 248 Tables
- Total Number of Pages: 803
Part III: Antibodies
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target Among Antibody Drugs in Oncology for
the Highest Therapeutic Outcome and Return on Investment (255 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies of
Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug
Targets Strategies and 531 Antibody Drugs)
- 8. Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications)
- 9. Pipeline and Portfolio Planning: Competitive Benchmarking of the
Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531
Antibody Drugs)
- 10. Disclaimer
- 11. Drug Index
- 12. Company Index
- Figures: Includes 5 Figures
- Tables: Includes 347 Tables
- Total Number of Pages: 1,944
This Report Includes the Following Companies:
- A&G Pharmaceutical
- Abbott
- Abiogen
- Ablynx
- Abraxis BioScience
- AC Immune
- Acceleron Pharma
- Access
- Actinium Pharmaceuticals
- Active Biotech
- Adherex
- Advanced Life Sciences
- Advantagene
- AEgera
- AEterna Zentaris
- Affibody
- Affimed Therapeutics
- Affitech
- AGY Therapeutics
- Aida Pharmaceuticals
- Alchemia
- Alder Biopharmaceuticals
- Alethia Biotherapeutics
- Alexion
- Alfacell
- Algeta
- Allos Therapeutics
- AlphaVax
- Alseres Pharmaceuticals
- ALSP
- Altor BioScience
- Ambrilia Biopharma
- Amgen
- Amorfix Life Sciences
- Anavex Life Sciences
- Antisense Pharma
- Antisoma
- Aphios
- ApopLogic Pharmaceuticals
- Apotex
- Apricus Biosciences
- Apthera
- Arana Therapeutics
- Arca biopharma
- Archer Biosciences
- arGEN-X
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Astellas
- AstraZeneca
- Attenuon
- Avaxia
- AVEO
- AVI BioPharma
- Bavarian Nordic
- Bayer
- Bellicum Pharmaceuticals
- Berkeley Lab
- BioAxone
- Biocon
- Bioenvision
- Biogen Idec
- BioInvent
- Biolex
- BioLineRx
- Bionovo
- Biosceptre
- Biostar
- Biotecnol
- Biotest
- BioVex
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Cadila
- Cancer Innovations
- Cancer Research Technology
- Cel-Sci
- Cell Genesys
- Cell Therapeutics
- Celldex Therapeutics
- Celltrion
- Celsion
- Celtic Pharma
- Center of Molecular Immunology
- Cephalon
- CG Therapeutics
- ChemGenex Pharmaceuticals
- ChemoCentryx
- Chemokine Therapeutics
- Circadian Technologies
- Coronado Biosciences
- Critical Outcome Technologies
- CSL
- CuraGen
- CureTech
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- CytImmune Sciences
- Cytochroma
- Cytokinetics
- Daewoong
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Debiopharm
- Dendreon
- DiaMedica
- Dompe
- Dongkook Pharm
- Dr Reddy' s
- Dyax
- ECI
- Eisai
- Elan
- Eleos
- Eli Lilly
- Emergent BioSolutions
- Endocyte
- EntreMed
- Enzon
- EpiCept
- Epitomics
- EUSA Pharma
- Exelixis
- Faron Pharmaceuticals
- Favrille
- Femta Pharmaceuticals
- FibroGen
- Five Prime Therapeutics
- Fusion Antibodies
- Galaxy Biotech
- GammaCan
- Ganymed Pharmaceuticals
- Gemin X Biotechnologies
- Gene Techno Science
- Genencor
- Genentech
- Generex
- Genmab
- Genomic Systems
- GenPat77
- Genta
- Genzyme
- Geron
- Gilead Sciences
- GlaxoSmithKline
- Gliknik
- Gloucester Pharmaceuticals
- GlycoGenesys
- Glycotope
- Got-a-Gene
- Green Cross
- Hawthorn Pharmaceuticals
- Hoffmann-La Roche
- Human Genome Sciences
- Idera Pharmaceuticals
- IDM Pharma
- ImClone Systems
- IMED
- Immune Pharmaceuticals
- ImmunoCellular Therapeutics
- Immunocore
- ImmunoGen
- Immunomedics
- Immutep
- Incyte Corporation
- Infinity Pharmaceuticals
- Innate Pharma
- InNexus Biotechnology
- Inovio
- Insmed
- Intracel
- Intradigm
- Introgen Therapeutics
- Ipsen
- ISA Pharmaceuticals
- Isis Pharmaceuticals
- ISU ABXIS
- Ivy Medical Chemicals
- Johnson & Johnson
- Kaketsuken
- KaloBios
- Kalypsys
- Kirin Pharma
- Kissei
- Kyowa Hakko Kirin
- Kyto Biopharma
- LEAD Therapeutics
- LFB Biotechnologies
- LG Life Sciences
- Ligand
- Lorus Therapeutics
- MacroGenics
- Mannkind
- Marillion Pharmaceuticals
- MAT Biopharma
- Medarex
- MediGene
- MedImmune
- Mediolanum
- Medisyn Technologies
- Menarini
- Merck & Co
- Merck KGaA
- Merrimack
- MethylGene
- Micromet
- Mitsubishi Tanabe Pharma
- Mojave Therapeutics
- Mycenax
- Nektar Therapeutics
- NeoPharm
- Neovacs
- Nerviano Medical Sciences
- Neuren
- NIH
- Nippon Shinyaku
- NKT Therapeutics
- Non-industrial source
- Northwest Biotherapeutics
- Novacea
- Novartis
- Novelix
- Novogen
- OncoGenex Pharmaceuticals
- OncoMed
- Onconova
- Oncothyreon
- Oncovir
- Onyvax
- Orion Pharma
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Paladin Labs
- Panacea
- PanaGin
- PanGenetics
- Pantarhei Bioscience
- Patrys
- Pepscan Therapeutics
- Peregrine Pharmaceuticals
- Perseus Proteomics
- Pfizer
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharminox
- Philogen
- Pierre Fabre
- Prima Biomed
- ProCell Therapeutics
- Prochon Biotech
- Progen
- Progenics Pharmaceuticals
- ProNAi Therapeutics
- ProStrakan
- Protox Therapeutics
- Ramot
- Reata Pharmaceuticals
- Recepta biopharma
- Receptor BioLogix
- Regeneron
- Regulon
- Rexahn
- Samyang
- Sanofi-Aventis
- Santaris Pharma
- SBI Biotech
- Scancell
- Seattle Genetics
- Semafore Pharmaceuticals
- Shenogen
- Shire
- Sigma-Tau
- SRI International
- Stainwei Biotech
- Sunol Molecular
- SuperGen
- SuppreMol
- Supratek Pharma
- Switch Pharma
- Symbiotec
- Symphogen
- Synageva BioPharma
- SynerGene Therapeutics
- Takeda
- Targa Therapeutics
- Tau Therapeutics
- Taxolog
- TeGenero
- Telik
- Teva
- Thallion Pharmaceuticals
- Therapure Biopharma
- Therion Biologics
- ThromboGenics
- Tigris Pharmaceuticals
- Titan Pharmaceuticals
- Tolerx
- TopoTarget
- Tracon Pharmaceuticals
- Transgene
- Trillium Therapeutics
- Trion Pharma
- UCB
- United Biomedical
- United Therapeutics
- Vaccinex
- Wakunaga
- Vascular Biogenics
- VasGene Therapeutics
- Vaxon Biotech
- Vertex Pharmaceuticals
- Wilex
- Vion Pharmaceuticals
- VioQuest
- Viragen
- Viralytics
- ViroTarg
- Viventia Biotech
- XBiotech
- Xencor
- Xerion
- Xoma
- Y' s Therapeutics
- YM BioSciences
- Zenotech
- ZymoGenetics
A Shortlist of Drugs Included are:
- 131I-tositumomab
- 2-methoxyestradiol
- abagovomab
- abarelix
- abiraterone acetate
- ABT-263
- AEG-35156
- aflibercept
- afutuzumab
- alemtuzumab
- alvocidib
- AMG-386
- Apomab
- ARQ-197
- AS-1411
- atiprimod dimaleate
- ATN-224
- belinostat
- bevacizumab
- bicalutamide
- brentuximab vedotin
- buserelin
- BZL-101
- canfosfamide hydrochloride
- catumaxomab
- CBLC-102
- celecoxib
- cenersen
- cetuximab
- cintredekin besudotox
- combretastatin A-4 prodrug
- conatumumab
- CS-1008
- dasatinib
- DCVax-prostate
- degarelix
- denosumab
- deslorelin
- docetaxel
- dulanermin
- dutasteride
- estramustine phosphate sodium
- ethinyl estradiol sulfonate
- farletuzumab
- flutamide
- galiximab
- GCS-100LE
- gemtuzumab ozogamicin
- girentuximab
- goserelin
- GRN-163L
- HE-3235
- histrelin
- ibritumomab tiuxetan
- idronoxil
- indisulam
- INGN-241
- INGN-401
- inotuzumab ozogamicin
- ipilimumab
- ISIS-23722
- kahalalide F
- leuprolide
- lonaprisan
- lumiliximab
- mapatumumab
- MDV-3100
- MGCD-0103
- MKC-1
- motexafin gadolinium
- nadroparin
- naptumomab estafenatox
- necitumumab
- nilutamide
- nimotuzumab
- obinutuzumab
- oblimersen sodium
- ofatumumab
- oregovomab
- panitumumab
- panobinostat
- PARP inhibitors
- PAT-SC1
- patupilone
- PCI-24781
- pertuzumab
- plitidepsin
- quarfloxacin
- ramucirumab
- Reditux
- retaspimycin
- Rh-Apo2L
- rituximab
- sagopilone
- seliciclib
- sunitinib malate
- tigapotide triflutate
- TLN-232
- toremifene citrate
- trastuzumab
- triciribine
- triptorelin
- triptorelin pamoate
- TRU-016
- voreloxin
- VX-944
- XL-647
- zalutumumab
- zanolimumab
- zibotentan
